Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2017
- GDHC4395CTIDB
- Pages: 55
- July 2017
- Total Views:1208
- Region : Global
- GlobalData
- Market Research Report

Details
Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2017
Summary
GlobalData's clinical trial report, "Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2017" provides an overview of Disseminated Intravascular Coagulation (DIC) clinical trials scenario. This report provides top line data relating to the clinical trials on Disseminated Intravascular Coagulation (DIC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Clinical Trials by G7 Countries: Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profile Snapshots 33
Appendix 53
Abbreviations 53
Definitions 53
Research Methodology 54
Secondary Research 54
About GlobalData 55
Contact Us 55
Source 55
List Of Figure
List of Figures
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 14
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 19
Disseminated Intravascular Coagulation (DIC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Disseminated Intravascular Coagulation (DIC) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31
GlobalData Methodology 54
List Of Table
List of Tables
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 15
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 20
Disseminated Intravascular Coagulation (DIC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Disseminated Intravascular Coagulation (DIC) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Disseminated Intravascular Coagulation (DIC) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Disseminated Intravascular Coagulation (DIC), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Asahi Kasei Corp
Kyowa Hakko Kirin Co Ltd
LEO Foundation
CSL Ltd
Company Profile
Company Profile Title
Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2017
Summary
GlobalData's clinical trial report, "Disseminated Intravascular Coagulation (DIC) Global Clinical Trials Review, H2, 2017" provides an overview of Disseminated Intravascular Coagulation (DIC) clinical trials scenario. This report provides top line data relating to the clinical trials on Disseminated Intravascular Coagulation (DIC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Clinical Trials by G7 Countries: Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profile Snapshots 33
Appendix 53
Abbreviations 53
Definitions 53
Research Methodology 54
Secondary Research 54
About GlobalData 55
Contact Us 55
Source 55
List Of Figure
List of Figures
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 14
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 19
Disseminated Intravascular Coagulation (DIC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Disseminated Intravascular Coagulation (DIC) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31
GlobalData Methodology 54
List Of Table
List of Tables
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, G7 Countries (%), 2017* 15
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Disseminated Intravascular Coagulation (DIC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Disseminated Intravascular Coagulation (DIC) to Hematological Disorders Clinical Trials, E7 Countries (%), 2017* 20
Disseminated Intravascular Coagulation (DIC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Disseminated Intravascular Coagulation (DIC) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Disseminated Intravascular Coagulation (DIC) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Disseminated Intravascular Coagulation (DIC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Disseminated Intravascular Coagulation (DIC) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Disseminated Intravascular Coagulation (DIC), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Asahi Kasei Corp
Kyowa Hakko Kirin Co Ltd
LEO Foundation
CSL Ltd